Job Cuts As Polyphor Focuses On First-In-Class Anticancer
And Cystic Fibrosis Antibiotic
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
You may also be interested in...
The Switzerland-headquartered group has suffered a setback as a couple of Phase III trials of its lead antibiotic were stopped temporarily after an unexpectedly high number of patients reported kidney injury.
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
AveXis/Novartis’s one-time AAV9 vector-based intravenous gene therapy for spinal muscular atrophy, Zolgensma, continues to have beneficial effects up to five years after its administration to babies, and an intrathecal formulation has significant promise in older infants.